Report of Foreign Issuer (6-k)
July 09 2018 - 7:12AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
Form 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For
the month of July 2018
Commission
File Number 001-37846
CELLECT
BIOTECHNOLOGY LTD.
(Translation
of registrant’s name into English)
23
Hata’as Street
Kfar
Saba, Israel 44425
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
This
Form 6-K (other than Exhibit 99.1) is incorporated by reference into the registrant’s Registration Statements on Form S-8
(Registration No. 333-214817 and 333-220015) and on Form F-3 (Registration No. 333-219614 and 333-212432).
On
July 9, 2018, Cellect Biotherapeutics Ltd. (the “Company”), a wholly owned subsidiary of Cellect Biotechnology Ltd.
(“Cellect”), entered into a Strategic Manufacturing and Supply Agreement (the “Agreement’) with Swiss
Biotech Center SA (“SBC”). Under the Agreement, the Company retained SBC as manufacturer of the FasL protein –
the main active ingredient in Cellect’s ApoGraft process and Apotainer selection kit.
According
to the Agreement, SBC granted to the Company exclusivity to the FasL protein developed by SBC for a period of five years, subject
to early termination of the exclusivity under certain conditions. The Agreement provides for the production of clinical batches
of the FasL protein in quantity and quality as shall be set forth in separate terms. Under the Agreement, Cellect agreed to pay
SBC an upfront payment of approximately $150,000 plus up to a further $300,000 upon the meeting of certain conditions.
The
Agreement has a term of ten years and may be extended by mutual written agreement for an additional term. The Agreement contains
customary early termination provisions and additionally may be early terminated by the Company if regulatory approval is not obtained
or SBC is unable to establish the requisite manufacturing process under the Agreement. The Agreement contains representations,
warranties and indemnification that are customary to commercial agreements of this nature.
Attached
hereto as Exhibit 99.1 and incorporated by reference herein is a press release issued by the Registrant entitled “Cellect
Signed Strategic Agreement with Swiss Biotech Center (SBC).”
Exhibit
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Cellect Biotechnology Ltd.
|
|
|
|
|
By:
|
/s/
Eyal Leibovitz
|
|
|
Name: Eyal Leibovitz
|
Date: July 9, 2018
|
|
Title: Chief Financial Officer
|
2
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Apr 2023 to Apr 2024